BenevolentAI – discover innovations in ALS treatment and medicine

Country
United Kingdom
Sustainable development goals
  • Good health and well-being
Project link
http://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=0e6f6b7a-c4fb-41c5-ad5c-c5e0bcbf4ac1&pnum=132

About the project

Previously, the fight against ALS has been long and hard with several expensive clinical trials not resulting in any significant breakthroughs. However, BenevolentAI are helping to change this through the use of artificial intelligence and machine learning. They use machine learning that can read natural languages, process data and generate new ideas, leading to cost and time efficiencies.

More project information

BenevolentAI run a series of projects aimed at improving the development of drugs and treatments for rare diseases. Machine learning enables the rapid development of new, life changing treatments and drugs, especially for diseases which were previously thought to be the most difficult to treat. Artificial intelligence is used to trawl through thousands of data sets, which if done by a human would take several lifetimes. This power augments human intelligence and allows for quicker and more accurate developments for treatment.

In the context of ALS, BenevolentAI’s machine learning technology has identified a promising compound that successfully prevents neuronal death in the in vitro patient-derived cell-based assay as well as delaying disease onset in a more common case of ALS. The technology is still working to find further developments in the treatment of ALS and further innovations can be expected soon.

BenevolentAI’s artificial intelligence is being used to help improve the discovery and development of new treatments for ALS, thus working towards SDG 3 (good health and wellbeing). Machine learning techniques have been applied to help accelerate discovery and improve the chances of success of potential ALS treatments.